Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from BTIG Research

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a research note issued on Monday, Benzinga reports. They presently have a $151.00 price objective on the stock. BTIG Research‘s price target points to a potential upside of 87.48% from the stock’s previous close.

A number of other research analysts also recently weighed in on the stock. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Wedbush set a $120.00 price target on shares of Oruka Therapeutics in a report on Thursday, September 24th. Guggenheim restated a “buy” rating and set a $200.00 price target on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, October 13th. Finally, UBS Group raised their price target on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $128.91.

Oruka Therapeutics Trading Up 1.8%

ORKA stock traded up $1.45 during midday trading on Monday, reaching $80.54. The company had a trading volume of 355,995 shares, compared to its average volume of 1,084,906. Oruka Therapeutics has a 1 year low of $25.11 and a 1 year high of $115.51. The company has a market capitalization of $5.33 billion, a P/E ratio of -39.71 and a beta of -0.37. The company has a 50 day moving average of $91.32 and a two-hundred day moving average of $80.65.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.04). On average, sell-side analysts anticipate that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insider Activity

In other news, SVP Arjun Agarwal sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the transaction, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $92.38, for a total transaction of $734,143.86. Following the transaction, the insider owned 31,771 shares in the company, valued at $2,935,004.98. This represents a 20.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 154,950 shares of company stock worth $14,102,680. 23.49% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ORKA. Nykredit A S bought a new position in Oruka Therapeutics in the 2nd quarter worth $29,000. GAMMA Investing LLC raised its holdings in Oruka Therapeutics by 201.6% in the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after acquiring an additional 250 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Oruka Therapeutics in the 4th quarter worth $67,000. Orion Capital Management LLC bought a new position in Oruka Therapeutics in the 2nd quarter worth $91,000. Finally, Royal Bank of Canada raised its holdings in Oruka Therapeutics by 178.5% in the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock worth $155,000 after acquiring an additional 2,033 shares during the period. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.